This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 20:33, 19 April 2011 (Updating {{chembox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 20:33, 19 April 2011 by CheMoBot (talk | contribs) (Updating {{chembox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation ()(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (April 2011) |
| |
| Names | |
|---|---|
| IUPAC name 3--6-(4-pentylphenyl)furopyrimidin-2-one | |
| Other names Cf1743 | |
| Identifiers | |
| 3D model (JSmol) | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
SMILES
| |
| Properties | |
| Chemical formula | C22H26N2O5 |
| Molar mass | 398.459 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
 Y verify (what is ?)
Infobox references
| |
FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity. It may be effective against shingles.
It was discovered in 1999.
Clinical trials
It is in a phase II trial against valaciclovir in patients with herpes zoster.
References
- Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
- McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - , 2010 http://www.dailymail.co.uk/health/article-515969/Thousands-spared-pain-shingles.html,
And at Cardiff University, Chris McGuigan, professor of medicinal chemistry, has developed a new drug for shingles, FV-100, which is doing well in phase I trials. FV 100 looks like it will be very potent (more than 10,000 times as strong as aciclovir), safe and could prevent long-term pain, too. It could be on the market by 2010.
{{citation}}: Missing or empty|title=(help) - Step forward for shingles drug - FV100 Shows structure of FV100
- A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |